GNH USA

Europe — EMA

Lanreotide Sun

GNH USA supplies Lanreotide Sun (Lanreotide), a somatostatin analog for acromegaly and neuroendocrine tumor treatment.

Lanreotide

Request sourcing

1
Pack/s

What is Lanreotide?

Lanreotide, the active ingredient in Lanreotide Sun, is a somatostatin analog presented as a long‑acting injectable formulation for subcutaneous use. It is employed to control excess hormone production in conditions such as acromegaly and neuroendocrine tumors in adult patients.

GNH USA supplies Lanreotide Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, throughout. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution, including batch release certificates and stability data.

What is Lanreotide used for?

Lanreotide is a somatostatin analog used to manage hormone‑secreting tumors and related disorders. - Acromegaly: reduces excess growth hormone secretion and normalizes IGF‑1 levels. - Neuroendocrine tumors: controls tumor‑related hormone secretion and can inhibit tumor growth. - Carcinoid syndrome: alleviates flushing and diarrhea by suppressing serotonin release.

What are the side effects of Lanreotide?

Lanreotide may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site pain - Nausea - Diarrhea - Headache

Serious or Rare Side Effects: - Gallbladder disease (cholelithiasis) - Pancreatitis - Severe hyperglycemia or diabetic ketoacidosis - Allergic reactions, including anaphylaxis - Cardiac arrhythmias - Severe abdominal pain

What precautions apply to Lanreotide?

When prescribing Lanreotide, several safety considerations should be observed. - Dose adjustment: renal or hepatic impairment may require closer monitoring. - Blood glucose monitoring: patients with diabetes may experience hyperglycemia. - Gallbladder monitoring: risk of gallstones; assess symptoms regularly. - Pregnancy: use only if potential benefit outweighs risk; safety not established. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

What does Lanreotide interact with?

Lanreotide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - CYP450 inducers (e.g., rifampicin): may lower Lanreotide exposure. - Co‑administration with other somatostatin analogs (e.g., octreotide): additive hormonal suppression. - Antidiabetic agents: risk of severe hyperglycemia when combined. - Quinidine: may increase risk of QT‑interval prolongation.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR values. - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: monitor electrolytes for potential imbalance.

Frequently asked questions

What is Lanreotide Sun used for?+
Lanreotide Sun is indicated for the treatment of acromegaly and for control of hormone secretion in neuroendocrine tumors, including carcinoid syndrome. It helps normalize growth‑hormone levels in acromegaly and reduces tumor‑related peptide release in neuroendocrine malignancies.
How does Lanreotide work?+
Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors 2 and 5 on target cells. This binding activates inhibitory signaling pathways that lower cyclic AMP and calcium influx, leading to reduced secretion of growth hormone, insulin, glucagon, and other peptide hormones.
What is the usual dose of Lanreotide Sun?+
The dosage and administration schedule for Lanreotide Sun are determined by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. The prescriber will select the appropriate dose and injection interval.
Is Lanreotide Sun safe during pregnancy or breastfeeding?+
Safety of Lanreotide Sun in pregnancy has not been established, and it should be used only if the potential benefit justifies any potential risk to the fetus. Limited data are available for breastfeeding; therefore, caution is advised and a risk‑benefit assessment should be performed.
How do I order Lanreotide Sun from GNH USA?+
To request Lanreotide Sun, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.
How does Lanreotide compare with the main alternative drug?+
The primary alternative in the same class is octreotide, another somatostatin analog. Both agents suppress hormone secretion, but Lanreotide has a longer dosing interval (often every 4‑8 weeks) compared with octreotide, which may require more frequent injections. Choice depends on clinical response, convenience, and physician preference.
What are the storage and handling requirements for Lanreotide Sun?+
Lanreotide Sun should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product. Before use, inspect the vial for particulate matter and ensure the solution is clear.
How is Lanreotide Sun administered?+
Lanreotide Sun is given by subcutaneous injection, typically using a pre‑filled syringe or autoinjector. The injection site is usually the abdomen or thigh. The prescribing clinician determines the injection frequency, which may range from monthly to every two months depending on the therapeutic indication.
What are the most serious risks associated with Lanreotide Sun?+
Serious adverse events include gallbladder disease such as cholelithiasis, pancreatitis, severe hyperglycemia that may lead to diabetic ketoacidosis, allergic reactions including anaphylaxis, and cardiac arrhythmias. Patients should be monitored for abdominal pain, elevated blood glucose, and any signs of hypersensitivity.
Who should not use Lanreotide Sun?+
Lanreotide Sun is contraindicated in patients with known hypersensitivity to lanreotide or any of its excipients. Caution is advised in individuals with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease. Pregnant women should only use it when the potential benefit outweighs the risk.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lanreotide
Route
Subcutaneous Use
Manufacturer
Sun Pharmaceutical Industries Europe B.V.
Origin
EU

Related products

Ipstyl

Ipstyl

Lanreotide

Ipsen S.P.A.
EU
Ipstyl Autogel

Ipstyl Autogel

Lanreotide

Institut Produits Synthèse (Ipsen) Ab
EU
Ipstyl Autogel

Ipstyl Autogel

Lanreotide

Institut Produits Synthèse (Ipsen) Ab
EU
Lanrenet

Lanrenet

Lanreotide

Mylan S.P.A.
EU